



Form PTO-1549

DOCKET NUMBER  
70332-4/USAPPLICATION NUMBER  
10/040,884

## INFORMATION DISCLOSURE CITATION

## BY APPLICANT

(Use s v r a l s h e t s i f n e c e s s a r y)

APPLICANT  
Ghildyal *et al.*FILING DATE  
January 7, 2002GROUP ART UNIT  
1646

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
PM	* 5,763,584	06-09-1998	Godowski	530	402	
	* 5,763,470	06-09-1998	Tang <i>et al.</i>	514	406	
	* 5,763,198	06-09-1998	Hirth <i>et al.</i>	435	7.21	
✓	* 5,763,441	06-09-1998	App <i>et al.</i>	514	249	

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
PM	WO 97/34920	09-25-1997	PCT	X	X		
PM	WO 95/30331	11-16-1995	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PM	* Shawver <i>et al.</i> , 1997, Receptor tyrosine kinases as targets for inhibition of angiogenesis, Drug Discovery Today, 2:50-63.
	* Herz <i>et al.</i> , 1997, Molecular approaches to receptors as targets for drug discovery, J. Recept. Signal Transduct. Res., 17:671-776.
	Marra <i>et al.</i> , The WashU-HHMI mouse EST project, EMBL ACC NO AA098024, 27 October 1996.
	Auffray <i>et al.</i> , IMAGE: integrated molecular analysis of the human genome and its expression, EMBL ACC NO Z42722, 6 November 1994.
✓	Rubin Grandis <i>et al.</i> , Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells, Oncogene, 15:409-416.

\* COPIES PREVIOUSLY SUBMITTED WITH THE PATENT APPLICATION, SERIAL NO. 09/310,438.

Prima Mentis 6/15/04

Form PTO-1449  <b>INFORMATION DISCLOSURE CITATION BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>	DOCKET NUMBER 70332-4/US	APPLICATION NUMBER 10/040,884
	APPLICANT Ghildyal <i>et al.</i>	
	FILING DATE January 7, 2002	GROUP ART UNIT 1646

**OTHER DOCUMENTS** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

PM	Chou <i>et al.</i> , 1987, Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin, J. Bio. Chem., 262:1842-1847.
EXAMINER  <i>Prerna Mung</i>	DATE CONSIDERED  <i>6/15/04</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	